炎症生物标志物和阿尔茨海默病:使用NULISAseq的试点研究
Guglielmo Di Molfetta1, Ilaria Pola1, Kubra Tan1
1Department of Psychiatry and Neurochemistry Institute of Neuroscience & Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Alzheimer's & dementia (Amsterdam, Netherlands)
|January 31, 2025
概括
这项研究确定了质纤维酸蛋白和S100A12作为阿尔茨海默病 (AD) 中的关键炎症生物标志物. 这些标记物在多次结解周期后保持稳定,这表明它们在阿尔茨海默病诊断中的实用性.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生化学
背景情况:
- 越来越多的证据将粉样β (Aβ) 聚合与神经炎症联系在一起.
- 阿尔茨海默病 (AD) 的特点是复杂的病理过程,包括炎症.
- 了解AD中的外周炎症标志物对于诊断进步至关重要.
研究的目的:
- 在阿尔茨海默病 (AD) 患者中研究与炎症相关的蛋白质的变化,使用一种新的免疫测试小组.
- 评估多次冷解周期 (FTCs) 后血清样本中蛋白质量定量的稳定性.
- 为了确定AD病理学的潜在外围生物标志物.
主要方法:
- 利用与核酸相关的免疫三明治测定 (NULISA) 炎症面板测量血清中的203种蛋白质.
- 分析了患有阿尔茨海默病理的和没有阿尔茨海默病理的个体的样本 (n=31个).
- 采用了根据年龄和性别调整的线性模型来比较蛋白质表达,并评估了五个FTC的影响.
主要成果:
- 质纤维酸蛋白和S100A12显示出AD病理存在的显著变化 (p < 0.001).
- 这些蛋白与脑脊液生物标志物相关联,包括酸化-181 (p-tau181),和Aβ42.
- 在5次FTC后,NULISA炎症小组在测量中显示出最小的变化,表明稳定性良好.
结论:
- 200个复合体的NULISA小组有效监测AD中循环炎症相关蛋白质的变化.
- S100A12被确定为AD的潜在外围生物标志物.
- 这些炎症标记物在FTC中的稳定性支持它们在临床诊断和研究中的使用.
关键词:
在GFAPAP中,GFAP是最重要的.努利萨 (Nulisa) 是一个无关紧要的人.在S100A12中,S100A12是S100A12中的一个.结解周期的周期这是一种炎症炎症炎症炎症.多重复合免疫检测试验新鲜的血液生物标志物样本的稳定性 样本的稳定性更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.2K
相关概念视频
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
